GLP-1 Comparison · April 29, 2026 · Prices Verified

Mounjaro vs Ozempic: Which Is Better in 2026?

Published: April 29, 2026

Written by The RX Index Editorial Team

Last verified: April 29, 2026 · FDA labels checked via DailyMed · Pricing verified · See methodology · Affiliate disclosure

Bottom line, verified April 29, 2026

Mounjaro vs Ozempic comes down to one question: are you after the largest possible drop in weight and A1C, or do you have a heart or kidney problem that needs the specific FDA-labeled indications only Ozempic carries?

Mounjaro (tirzepatide) wins for raw weight and A1C reduction. Ozempic (semaglutide) wins when its labeled cardiovascular and kidney indications matter. Neither is FDA-approved for weight loss alone — for that, you're actually shopping Zepbound vs Wegovy.

List prices: $1,112.16 per 28-day fill (Mounjaro) and $1,027.51 per fill (Ozempic) before any insurance, savings cards, or cash-pay programs.

There's also a third group reading this page who shouldn't be comparing these two at all. We'll be honest about who that is in a minute, even if it costs us the click. Stay with us — the answer is faster and more useful than the page-1 results that brought you here.

Affiliate disclosure. The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We may earn a commission if you use some of the links on this page. Commissions never change which medication is medically right for you, and our editorial conclusions are based on FDA labels, published trial evidence, and current public pricing — not on what pays best.

Medical disclaimer. This is not medical advice. Talk to a licensed clinician before starting, switching, or stopping any prescription medication.

The 30-second decision

Before you scroll, this is the answer for most people:

What we verified for this page

We don't expect you to take our word for any of this. Here's the receipt.

Verified on April 29, 2026:

• FDA labels for Mounjaro and Ozempic via DailyMed (the NIH's official drug-label database).
• Mounjaro list price of $1,112.16 per 28-day fill via Eli Lilly's official Mounjaro pricing page and FAQ. One fill is defined as a month's supply of four pens.
• Ozempic list price of $1,027.51 and self-pay tiers ($349/mo for 0.25–1 mg, $499/mo for 2 mg, $199 intro for the first two months on starting doses through June 30, 2026) via NovoCare's official Ozempic savings and pricing pages.
• SURPASS-2 head-to-head trial results via the original New England Journal of Medicine publication and Eli Lilly's clinical-trial press release.
• SURPASS-CVOT cardiovascular outcomes (tirzepatide vs dulaglutide) via the American College of Cardiology summary and the published primary endpoint.
• November 2025 White House GLP-1 pricing agreement via the Novo Nordisk and Eli Lilly press releases announcing implementation.
• Medicare Part D rules and 2026 $2,100 out-of-pocket cap via CMS.gov; Medicare GLP-1 Bridge announcement (effective July 1, 2026) via CMS.
• Ro's GLP-1 Insurance Coverage Checker, Body program pricing, and Mounjaro availability status via ro.co.

Needs final verification before going live:

• Live Bing autocomplete and PAA exact wording on publish day.
• Whether Eli Lilly has launched a consumer Mounjaro program through LillyDirect (the November 2025 commitment was to bring Mounjaro to LillyDirect at 50–60% off list; as of late April 2026 only Zepbound has the consumer vial program at $299–$449/month).
• Current Sesame Care branded GLP-1 pricing and Costco-member pricing on Wegovy and Ozempic.

We re-verify every commercial fact on this page on a 30-day cadence. The "Last verified" date at the top of the page updates when we do.

The 2026 Mounjaro vs Ozempic master comparison

Every dimension that should drive your decision, in one place.

The next sections turn this table into a decision for your situation.

The single most important fact about Mounjaro vs Ozempic

Here's the honest version, which is the one most ranking pages bury six headings deep:

Here's the brand map, because the four-way confusion ends up costing real people real money:

If you're reading this page because you want to lose weight and you don't have type 2 diabetes, here's our damaging admission: you're researching the wrong two drugs. You should be on our Wegovy vs Zepbound comparison instead. Wegovy and Zepbound are FDA-approved for chronic weight management. Insurance is more likely to cover them for that purpose. Zepbound also has an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity. Both have manufacturer cash-pay programs that genuinely make them affordable — Wegovy via NovoCare ($199 intro, $349 standard for most doses) and Zepbound vials via LillyDirect ($299–$449 after the November 2025 pricing reset). Mounjaro doesn't have a cash-pay program at all right now. Ozempic does, but its self-pay tiers are higher than Wegovy's.

We say this knowing some of you will leave. That's fine. The right reader for the rest of this page is going to trust everything we say next more for it, because we said this out loud instead of pretending the search term you typed was always the right question.

For everyone still here — readers with type 2 diabetes, readers already prescribed off-label, readers comparing both drugs for a specific medical reason — the Mounjaro vs Ozempic comparison is the right comparison, and we're going to do it properly.

Mounjaro vs Ozempic for weight loss

Now the nuance, because anyone who tells you "Mounjaro is twice as effective" is overselling.

SURPASS-2 compared Mounjaro to Ozempic 1 mg, not Ozempic 2 mg. The 2 mg dose of Ozempic was approved in March 2022, around the same time that trial was wrapping up. The closest data we have on Ozempic 2 mg comes from SUSTAIN FORTE, which compared semaglutide 2 mg vs 1 mg in adults with type 2 diabetes and found an average weight loss of 6.9 kg vs 6.0 kg at week 40 (trial-product estimand). The 2 mg dose adds modestly to Ozempic's weight-loss effect — narrowing the gap with Mounjaro, but not closing it.

Two clean numbers worth remembering:

Plain-English bottom line on weight loss:

• If your top priority is the largest average weight loss and your insurance situation is comparable for both drugs, Mounjaro is the medication to ask your clinician about first.
• If you've plateaued on Ozempic and your weight isn't moving anymore, that's a legitimate reason to ask about switching to Mounjaro.
• If you don't have type 2 diabetes and your only goal is weight loss, the right comparison is Zepbound vs Wegovy.

Mounjaro vs Ozempic for diabetes (A1C and blood sugar)

Both drugs are FDA-approved as add-ons to diet and exercise to improve glycemic control. Both work weekly. Both reduce A1C significantly in trials and in clinical practice. The differences that matter:

Mounjaro's A1C edge. Across the three doses studied in SURPASS-2 (5, 10, 15 mg), Mounjaro reduced A1C by 2.01%, 2.24%, and 2.30% respectively. Ozempic 1 mg reduced A1C by 1.86%. That's a real, statistically significant gap — and it's why endocrinologists have leaned toward tirzepatide in patients who need aggressive A1C lowering.

Ozempic's dose ceiling. Ozempic now goes up to 2 mg weekly, which produces additional A1C reduction beyond 1 mg. That narrows but doesn't eliminate the gap.

The dose-equivalence question. There is no FDA-approved or universally accepted conversion chart between Mounjaro doses and Ozempic doses. Some clinicians use a rough rule of thumb (Mounjaro 5 mg ≈ Ozempic 1 mg in A1C effect), but this isn't validated. If you're switching, your clinician will almost certainly start you at the new drug's lowest dose and titrate up.

Mounjaro vs Ozempic side effects

Here are the actual side-effect rates from each drug's FDA prescribing information. They're not perfectly comparable across drugs (different trials, different populations) but they're the cleanest data publicly available.

The discontinuation rate — patients who stopped because of GI side effects — is in the low single digits for both drugs at typical doses, slightly higher for Mounjaro at the 15 mg dose.

Both drugs share serious warnings that you and your prescriber should review:

• Thyroid C-cell tumors: Boxed warning. Don't take either if you or a family member has had medullary thyroid carcinoma or have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Pancreatitis: Stop the medication and call your clinician immediately for severe abdominal pain.
• Gallbladder disease: Both can increase risk.
• Diabetic retinopathy worsening: A specific warning on the Ozempic label, especially in patients with established retinopathy.
• Kidney injury: Severe vomiting or diarrhea can cause dehydration that worsens kidney function.
• Low blood sugar (hypoglycemia): Especially when combined with insulin or sulfonylureas. Your clinician may reduce other diabetes meds when starting either drug.
• Allergic reactions: Including anaphylaxis and angioedema.

What real users are asking on Reddit and patient forums: "Which drug has had less side effects? I am so fatigued on Ozempic." and "Which was easier to take, or which had better efficacy?" — these are the exact questions readers bring to this comparison. We include them not as evidence (they're not), but to acknowledge that tolerability varies enormously person to person. Some people sail through both with minor nausea on day 2 of each dose increase. Others can't tolerate Mounjaro 15 mg or Ozempic 2 mg at all and have to step back. Your clinician will work with you to find a tolerable dose.

Practical advice that helps almost everyone:

• Titrate slowly — don't push to the next dose if you're still queasy at the current one.
• Eat smaller, lower-fat meals, especially in the first few days after a shot.
• Hydrate aggressively. GI losses can sneak up on you.
• Take an antiemetic (like ondansetron) if your clinician prescribes one for the first dose increase.
• Call your clinician for severe or persistent symptoms.

Mounjaro vs Ozempic if you have heart disease or kidney disease

This is the dimension where the comparison flips most decisively. Mounjaro has the bigger A1C and weight numbers. Ozempic has the bigger label.

Ozempic's cardiovascular indication comes from the SUSTAIN-6 trial, which showed semaglutide reduced major adverse cardiovascular events in adults with T2D and existing cardiovascular disease. The FDA approved this indication in 2020.

Ozempic's kidney indication comes from the FLOW trial, published in 2024. Semaglutide reduced the risk of major kidney disease events, a sustained drop in kidney function, and death from cardiovascular causes in adults with T2D and chronic kidney disease.

What about Mounjaro's cardiovascular trial? SURPASS-CVOT results are now published. The trial tested tirzepatide against dulaglutide (a different GLP-1, not a placebo) in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. The primary endpoint of major adverse cardiovascular events occurred in 12% of tirzepatide patients vs 13% of dulaglutide patients (hazard ratio 0.92). Tirzepatide met the bar for noninferiority but did not show superiority to dulaglutide for cardiovascular event reduction. That doesn't mean Mounjaro doesn't help the heart — it means the trial showed equivalence to another GLP-1, not superiority over standard care, and the FDA has not added a cardiovascular risk-reduction indication to the Mounjaro label.

What this means for you:

• If you have T2D plus a history of heart attack, stroke, coronary artery disease, peripheral artery disease, or established cardiovascular disease — ask about Ozempic first. The label backs it up.
• If you have T2D plus chronic kidney disease (eGFR <60 or albuminuria) — ask about Ozempic first.
• If your primary issue is A1C and weight without cardiovascular or kidney complications — Mounjaro is a reasonable first ask.

How much do Mounjaro and Ozempic cost in 2026?

This is the section most pages on page 1 of search results get wrong, because they were written before the November 2025 White House pricing reset. Here's the reality, with timestamps.

The 2026 cost reality matrix

Every commercial number above was verified against the manufacturer's official pricing pages within the last 30 days.

The November 2025 White House pricing reset

In November 2025, the federal government negotiated pricing agreements with both Eli Lilly and Novo Nordisk on GLP-1s. Novo Nordisk implemented immediately — that's why the new $349/$499 NovoCare tiers and the $199 intro exist. The standard self-pay price for Ozempic dropped from $499 to $349 in the same announcement. Eli Lilly committed to bringing diabetes-side discounts on Trulicity and Mounjaro to LillyDirect at 50–60% off list, but as of late April 2026 the consumer-facing Mounjaro program has not launched. The closest legitimate cash-pay path for tirzepatide remains LillyDirect's Zepbound vial program at $299–$449/month — but that's a different FDA-approved drug for a different FDA-approved indication (chronic weight management and obstructive sleep apnea).

If you're a self-pay Mounjaro patient watching this space, this is the single biggest update to track between now and the end of 2026.

Why "list price" is almost never what you'll actually pay

Three numbers to keep straight:

1. List price (also called WAC, wholesale acquisition cost): What Eli Lilly and Novo Nordisk charge wholesalers. Almost no patient pays this.
2. Cash-pay price (manufacturer programs): What you pay if you skip insurance and buy directly from the manufacturer's program. This is the NovoCare $349/$499 number for Ozempic.
3. Insurance copay: What you actually pay at the pharmacy after insurance, prior authorization, and any savings card.

Most insured T2D patients fall into bucket 3 and pay $25/mo with the manufacturer savings card. Most uninsured Ozempic patients fall into bucket 2 and pay $349/mo. Almost nobody pays bucket 1.

Will insurance cover Mounjaro or Ozempic?

What commercial insurance usually covers

Most commercial health plans cover both Ozempic and Mounjaro for adults with type 2 diabetes, often with prior authorization and step therapy. Common requirements:

• Diagnosis on file: ICD-10 code for T2D (E11.x).
• Prior authorization: Your prescriber submits documentation proving medical necessity. Approval typically takes 1–10 business days.
• Step therapy (often called fail-first): Some plans require you to try metformin first, and sometimes a second-line drug, before they'll cover a GLP-1. Documentation that earlier therapies were ineffective or not tolerated unlocks coverage.
• Quantity limits: Usually one box of pens per 28 days.

What commercial insurance usually doesn't cover

Off-label weight loss without T2D. If your prescription is written for weight management and you don't have a diabetes diagnosis, expect a denial. The standard advice: ask your clinician whether Wegovy or Zepbound (the FDA-approved weight-loss versions) would be more appropriate. Plans that exclude weight-loss drugs entirely will deny both, but plans that include obesity benefits are far more likely to cover Wegovy or Zepbound for documented obesity than Ozempic or Mounjaro off-label.

Medicare in 2026

• Part D for T2D: Both drugs are covered. For Mounjaro specifically, Eli Lilly reports that about 8 in 10 Medicare Part D patients pay $0–$50 per 28-day supply; remaining patients average about $262. The 2026 Part D benefit redesign capped annual out-of-pocket spending on covered drugs at $2,100.
• Part D for weight loss alone: Not covered. Federal law excludes weight-loss drugs from Part D. CMS proposed changing this in late 2024; the final rule in April 2025 declined to do so.
• Medicare GLP-1 Bridge: Beginning July 1, 2026, CMS is launching a separate program that will offer eligible Medicare beneficiaries a $50/month copay for certain GLP-1 medications used for weight management — outside the standard Part D benefit. Eligibility and covered drugs are still being finalized.
• Manufacturer savings cards: Cannot be used by Medicare, Medicaid, VA, TRICARE, or other government beneficiaries. This is a federal anti-kickback rule.

Medicaid

State by state. As of late 2025, only about 13 states cover obesity medications under Medicaid, and several (including California and Pennsylvania) eliminated coverage effective January 1, 2026. T2D coverage is more consistent but typically requires prior authorization. Check your state's Medicaid formulary.

How Ro fits into the insurance picture

Ro doesn't replace your insurance — it works alongside it. The Ro Body program is cash-pay only ($39 first month, then $149/mo or as low as $74/mo with annual prepay; medication priced separately). Ro's insurance concierge handles prior authorization paperwork on FDA-approved GLP-1s and works with your insurance company to get coverage approved; the process takes about 2–3 weeks.

Important to know: Ro does not currently offer Mounjaro. The drugs Ro can prescribe and provide insurance support for are Ozempic, Wegovy, and Zepbound (plus Foundayo, the new oral GLP-1). For Mounjaro specifically, your access path is your primary care or specialist clinician plus the Lilly Mounjaro Savings Card if you're commercially insured. For everything else — Ozempic, Wegovy, Zepbound — Ro is the cleanest single-stop telehealth option.

Which one should you ask about? Decision tree by situation

Can you switch from Ozempic to Mounjaro (or Mounjaro to Ozempic)?

Reasons people switch (in order of frequency)

1. Plateau. Weight loss stalled on the current drug. Switching to the other class can reset progress.
2. GI tolerability. Severe nausea, vomiting, or diarrhea on the current drug. Some people genuinely tolerate one molecule and not the other.
3. Insurance coverage change. Your formulary changed at open enrollment, or your employer switched plans, and the drug you were on is no longer covered.
4. New diagnosis. Heart disease or kidney disease appeared, and Ozempic's labeled indications now matter more.

How the switch usually works

Mounjaro stays in your system for about 25 days; Ozempic stays for about 5 weeks. Most clinicians:

• Wait one weekly dose cycle past your last shot of the old drug.
• Start you at a lower dose of the new drug than the equivalent on the old drug — often the lowest starting dose (Mounjaro 2.5 mg or Ozempic 0.25 mg).
• Re-titrate over 4-week intervals, checking tolerance.

If you're switching because of GI side effects, your clinician may want symptoms to fully resolve before starting the new drug — that can mean a 2–4 week pause.

Things to know before you ask

• No validated dose-equivalence chart. Don't trust internet graphics that say "Ozempic 1 mg = Mounjaro 5 mg." There isn't one.
• Switching may not restart weight loss. Most people see additional loss; some see equivalent results; a few see worse. There's no guarantee.
• Plan for the insurance back-and-forth. A switch often triggers a new prior authorization. Build in 2–4 weeks before your current supply runs out.
• GI side effects can return on the new drug. Restarting at a lower dose helps, but the first 4–8 weeks of any new GLP-1 typically include nausea on dose increases.

For a deeper switching framework, see our How to Switch from Semaglutide to Tirzepatide guide.

Can you take Mounjaro and Ozempic together?

People ask this question for predictable reasons: they think more must be better, they're plateauing and looking for any edge, they're switching and confused about overlap, or they have leftover pens. None of these are reasons to combine the drugs. If you're plateauing, ask about switching. If you're switching, your clinician will tell you when to stop the first drug and start the second. If you have leftover pens from a previous prescription, don't use them to stack therapy — store them per the label until your clinician advises otherwise, or use an approved medication take-back option for safe disposal.

How we made this comparison (methodology)

We're showing our work because health pages should.

FDA labels for both drugs were pulled from DailyMed (the NIH's official drug-label database) on April 29, 2026. Anything we say about FDA-approved indications, dosing, or safety warnings is sourced to the current label.

Head-to-head clinical evidence is from the SURPASS-2 trial, published June 25, 2021 in The New England Journal of Medicine. Real-world reinforcement comes from a 2024 JAMA Internal Medicine study comparing tirzepatide to semaglutide in routine clinical practice. Cardiovascular outcomes data on tirzepatide comes from SURPASS-CVOT.

Side-effect rates are from each drug's current FDA prescribing information. We disclosed that rates aren't directly comparable across separate trials.

Pricing was verified on the official manufacturer pages on April 29, 2026:

• Mounjaro: pricinginfo.lilly.com/mounjaro and the Mounjaro FAQ page.
• Ozempic: novocare.com (Ozempic Savings Offer page and explaining-list-price page).

Insurance and Medicare coverage rules were verified via CMS.gov, current Medicare Part D plan documents, and the FDA's published rules on manufacturer savings cards.

The November 2025 White House pricing agreement implementation status was verified via the Novo Nordisk press release ("Novo Nordisk launches introductory self-pay offer for Wegovy and Ozempic for $199 per month," November 17, 2025) and Eli Lilly's announcement of the same.

Provider details for Ro were verified directly on ro.co, including the GLP-1 Insurance Coverage Checker, Ro Body pricing, the Ro Mounjaro page (which states Ro does not currently offer Mounjaro), and the insurance navigation timeline.

What we didn't do: We didn't take payment from any drug manufacturer in exchange for placement. We didn't fabricate testimonials. We didn't cite forum posts as evidence for medical claims — we used Reddit and patient-forum quotes only to surface the real questions readers are asking, with explicit framing that they aren't medical evidence.

Our editorial judgment standard: Editorial conclusions on this page are based on verified label facts, published evidence, and current public pricing/access information. They are not medical advice and do not replace a clinician's judgment.

Our re-verification cadence: Every commercial number on this page is re-checked on a 30-day cycle. The "Last verified" date at the top of the page updates when we re-check. If you're reading this 6+ months after that date, treat the pricing numbers as approximate and click through to the manufacturer page to confirm current pricing.

Mounjaro vs Ozempic FAQ

Still not sure which GLP-1 is right for you?

You've made it this far. You know more about Mounjaro vs Ozempic than 99% of the people who searched for it today. If the right answer for you is still fuzzy, that's because the right answer depends on your situation — and we don't know yours.

Take our free 60-second GLP-1 matching quiz. It asks about your goals (weight loss, blood sugar, both), your insurance, your medical history, your budget, and your tolerance for monthly injections. Then it routes you to the FDA-approved medication and provider path that actually fits — Mounjaro, Ozempic, Zepbound, Wegovy, Foundayo, or a different option entirely. No email required to see your result.

If you already know what you need, here's where to go next:

• Insurance coverage check for Ozempic, Wegovy, and Zepbound (free, all in one report): Run my coverage check →
• Cash-pay branded GLP-1 access (Wegovy, Zepbound, Foundayo, Ozempic at NovoCare/LillyDirect pricing, with insurance concierge): Start a Ro Body intake →
• Switching from one to the other: How to Switch from Semaglutide to Tirzepatide
• Weight-loss-only readers: Wegovy vs Zepbound: 2026 Comparison
• Live pricing tracker: GLP-1 Pricing Change Log (coming soon — updated each time NovoCare or LillyDirect posts a new price).

This page was produced by The RX Index Editorial Team. The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We re-verify every commercial fact on this page on a 30-day cadence; the "Last verified" date at the top of the page updates when we re-check.

Last verified: April 29, 2026.

Sources

1. Eli Lilly. "Mounjaro Cost Information | With or Without Insurance." pricinginfo.lilly.com/mounjaro and mounjaro.lilly.com/faq. Mounjaro list price: $1,112.16 per 28-day fill (one fill = four pens).
2. Novo Nordisk. "Ozempic Pricing." novopricing.com/ozempic.html. Ozempic WAC: $1,027.51 per fill.
3. Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med 2021;385:503-515. SURPASS-2.
4. DailyMed. "MOUNJARO (tirzepatide) injection prescribing information." Updated 2026. dailymed.nlm.nih.gov.
5. NovoCare. "Get savings and support for Ozempic." novocare.com/diabetes/products/ozempic/savings-offer.html. Self-pay tiers and intro offer dates.
6. Ro. "GLP-1 Insurance Coverage Checker." ro.co/weight-loss/glp1-insurance-checker.
7. DailyMed. "OZEMPIC (semaglutide) injection prescribing information." Updated 2026. dailymed.nlm.nih.gov.
8. American College of Cardiology. "SURPASS-CVOT: Is Tirzepatide Superior to Dulaglutide in Patients With T2D and ASCVD?" Primary endpoint: 12% (tirzepatide) vs 13% (dulaglutide); HR 0.92; noninferiority met, superiority not met.
9. Novo Nordisk press release, November 17, 2025: "Novo Nordisk launches introductory self-pay offer for Wegovy and Ozempic for $199 per month." Eli Lilly Zepbound LillyDirect pricing announcement, November 2025.
10. Centers for Medicare & Medicaid Services. 2026 Part D benefit redesign and out-of-pocket cap. Medicare GLP-1 Bridge effective July 1, 2026. cms.gov.
11. Ro. "Weight Loss Program Pricing." ro.co/weight-loss/pricing. Ro Body membership: $39 first month, then $149/month or as low as $74/month with annual prepay.
12. Ro. "Mounjaro for Weight Loss" page. ro.co/weight-loss/mounjaro. Ro states Mounjaro is not currently offered.
13. Frías JP, Auerbach P, Bajaj HS, et al. "Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE)." Lancet Diabetes Endocrinol 2021. Weight loss: 6.9 kg vs 6.0 kg at week 40 (trial-product estimand).
14. Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. "Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity." JAMA Internal Medicine, 2024.
15. Ro. Insurance navigation page. ro.co/weight-loss/insurance. Ro states the concierge process takes about 2–3 weeks.
16. U.S. Food and Drug Administration. "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." fda.gov.